A 28-year-old woman with Crohn's disease (CD) of 8 years' duration presents with a 3-month history of progressive right lower abdominal pain, palpable mass in the right iliac fossa, and weight loss (4 kg). She is afebrile, with normal WBC and CRP. Contrast-enhanced CT abdomen shows a 6 cm stricture in the terminal ileum with proximal bowel dilatation and a small fistula to the adjacent small bowel loop. She is currently on mesalamine monotherapy. What is the most appropriate next step in management?

Question

Accepted Answer

B. Refer for surgical resection of the strictured segment with primary anastomosis. ## Clinical Presentation: Structuring Crohn's Disease with Fistulization

This patient demonstrates **complicated CD** with:
- **Stricturing phenotype:** 6 cm terminal ileal stricture with proximal dilatation (mechanical obstruction risk)
- **Fistulizing disease:** small bowel-to-bowel fistula
- **Chronicity:** 8-year disease duration with inadequate medical control on mesalamine monotherapy
- **Absence of active inflammation:** afebrile, normal WBC, normal CRP (suggests fibrostenosing rather than inflammatory pathology)

## Pathophysiology: Why Medical Therapy Fails in Stricturing Disease

**Key Point:** Strictures in CD are primarily **fibrotic** (collagen deposition and smooth muscle hypertrophy), not inflammatory. Biologics and corticosteroids target inflammation and are ineffective for established fibrotic strictures.

**High-Yield:** The Montreal Classification divides CD phenotypes:
- **Inflammatory (B1):** responsive to medical therapy
- **Stricturing (B2):** fibrotic; medical therapy fails
- **Penetrating (B3):** fistulizing; requires escalation or surgery

This patient has **B2 + B3** (stricturing + fistulizing) disease.

## Decision Algorithm: When to Operate in CD

```mermaid
flowchart TD
  A[Crohn's disease with stricture/fistula]:::outcome --> B{Active inflammation?}:::decision
  B -->|Yes, mild-moderate| C[Optimize medical therapy: biologics + corticosteroids]:::action
  B -->|No, fibrotic stricture| D[Assess for obstruction symptoms]:::decision
  D -->|Recurrent obstruction or fistula| E[Surgical resection]:::urgent
  D -->|Asymptomatic stricture| F[Observe or consider endoscopic dilation]:::action
  E --> G[Resect diseased segment + primary anastomosis]:::action
  C --> H{Response at 8-12 weeks?}:::decision
  H -->|Yes| I[Continue maintenance]:::action
  H -->|No| J[Escalate or consider surgery]:::urgent
```

## Why Surgery Is Indicated Here

| Feature | Implication |
|---------|-------------|
| 6 cm stricture | Likely fibrotic; high risk of obstruction |
| Fistula present | Penetrating disease; medical therapy alone insufficient |
| Normal inflammatory markers | Suggests fibrosis, not active inflammation |
| Inadequate response to mesalamine | 8 years on monotherapy = failed medical control |
| Palpable mass + symptoms | Symptomatic disease requiring intervention |

**Clinical Pearl:** Surgery is **not contraindicated** in CD and is often necessary for:
- Symptomatic strictures with obstruction
- Fistulizing disease unresponsive to medical therapy
- Perforation or abscess
- Dysplasia or malignancy

Resection of the diseased terminal ileum with primary ileocolic anastomosis is the standard approach.

## Why Other Options Fail

**Option A (Escalate mesalamine + budesonide):**
- Budesonide is for inflammatory flares, not fibrotic strictures
- Will not reverse established fibrosis or resolve fistula
- Delays necessary surgical intervention

**Option B (Infliximab induction):**
- Biologics are most effective for **inflammatory** CD
- Fibrotic strictures do not respond to TNF-α inhibitors
- Fistulas may respond to infliximab, but the stricture will persist
- Patient already has 8 years of disease with inadequate control — escalation is unlikely to succeed

**Option D (Endoscopic dilation):**
- Stricture is 6 cm long (too long for safe dilation)
- Fistula present increases perforation risk during dilation
- Temporary measure only; recurrence is high in CD
- Not appropriate as primary therapy for symptomatic stricturing disease

[cite:Harrison 21e Ch 295; Robbins 10e Ch 17]

![Inflammatory Bowel Disease diagram](https://mmcphlazjonnzmdysowq.supabase.co/storage/v1/object/public/blog-images/explanation/3010.webp)

Answer

A. Perform double-balloon enteroscopy for stricture dilation and fistula assessment

Answer

C. Increase mesalamine dose to 4.8 g/day and add oral budesonide 9 mg/day

Answer

D. Initiate infliximab induction therapy (5 mg/kg IV at weeks 0, 2, 6) and continue mesalamine

Explanation

Clinical Presentation: Structuring Crohn's Disease with Fistulization

Pathophysiology: Why Medical Therapy Fails in Stricturing Disease

Decision Algorithm: When to Operate in CD

Why Surgery Is Indicated Here

Why Other Options Fail

Practice similar questions

Join our NEET PG community

Feature	Implication
6 cm stricture	Likely fibrotic; high risk of obstruction
Fistula present	Penetrating disease; medical therapy alone insufficient
Normal inflammatory markers	Suggests fibrosis, not active inflammation
Inadequate response to mesalamine	8 years on monotherapy = failed medical control
Palpable mass + symptoms	Symptomatic disease requiring intervention